Entourage Health Corp. (ENTG.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.7 Million CAD | 127.35% |
| 2022 | -19.89 Million CAD | -69.79% |
| 2021 | -11.71 Million CAD | 51.6% |
| 2020 | -24.2 Million CAD | -262.76% |
| 2019 | 14.87 Million CAD | 220.93% |
| 2018 | 4.63 Million CAD | 1754.37% |
| 2017 | 249.89 Thousand CAD | 41.51% |
| 2016 | 176.59 Thousand CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.17 Million CAD | -80.2% |
| 2024 Q1 | 5.95 Million CAD | 235.9% |
| 2023 FY | 5.43 Million CAD | 127.35% |
| 2023 Q1 | 3.99 Million CAD | 132.17% |
| 2023 Q4 | -4.37 Million CAD | -279.52% |
| 2023 Q2 | 3.05 Million CAD | -23.44% |
| 2023 Q3 | 2.43 Million CAD | -20.25% |
| 2022 Q2 | -3.44 Million CAD | -277.92% |
| 2022 Q3 | -5.96 Million CAD | -72.84% |
| 2022 FY | -19.89 Million CAD | -69.79% |
| 2022 Q1 | 1.93 Million CAD | 185.7% |
| 2022 Q4 | -12.41 Million CAD | -108.29% |
| 2021 FY | -11.71 Million CAD | 51.6% |
| 2021 Q3 | -10.28 Million CAD | -1234.37% |
| 2021 Q4 | -2.26 Million CAD | 78.0% |
| 2021 Q2 | 906.5 Thousand CAD | 1290.02% |
| 2021 Q1 | -76.17 Thousand CAD | 99.76% |
| 2020 Q3 | 12.16 Million CAD | 375.28% |
| 2020 Q4 | -31.36 Million CAD | -357.94% |
| 2020 Q1 | -582.4 Thousand CAD | -406.49% |
| 2020 Q2 | -4.41 Million CAD | -658.48% |
| 2020 FY | -24.2 Million CAD | -262.76% |
| 2019 Q3 | -7.82 Million CAD | -140.75% |
| 2019 Q1 | 3.31 Million CAD | 508.55% |
| 2019 Q2 | 19.19 Million CAD | 479.38% |
| 2019 Q4 | 190.02 Thousand CAD | 102.43% |
| 2019 FY | 14.87 Million CAD | 220.93% |
| 2018 Q2 | 2.01 Million CAD | 214.99% |
| 2018 FY | 4.63 Million CAD | 1754.37% |
| 2018 Q4 | -810.72 Thousand CAD | -129.06% |
| 2018 Q3 | 2.78 Million CAD | 38.42% |
| 2018 Q1 | 639.81 Thousand CAD | 1207.02% |
| 2017 Q2 | -130.4 Thousand CAD | -191.13% |
| 2017 FY | 249.89 Thousand CAD | 41.51% |
| 2017 Q4 | 48.95 Thousand CAD | -74.0% |
| 2017 Q1 | 143.09 Thousand CAD | 219.47% |
| 2017 Q3 | 188.25 Thousand CAD | 244.36% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | -119.77 Thousand CAD | -140.41% |
| 2016 Q3 | 296.36 Thousand CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | 176.59 Thousand CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 5499.00 CAD | -67324.95% |
| CanadaBis Capital Inc. | 11.78 Million CAD | 68.535% |
| Decibel Cannabis Company Inc. | 41.85 Million CAD | 91.142% |
| Delivra Health Brands Inc. | 6.39 Million CAD | 42.058% |
| Lifeist Wellness Inc. | 5.34 Million CAD | 30.623% |
| Cannara Biotech Inc. | 27.23 Million CAD | 86.384% |
| Medicure Inc. | 13.98 Million CAD | 73.496% |
| PharmaCielo Ltd. | -1.36 Million CAD | 370.865% |
| Rubicon Organics Inc. | 13.14 Million CAD | 71.785% |
| BioSyent Inc. | 25.14 Million CAD | 85.253% |
| Voyageur Pharmaceuticals Ltd. | -2185.00 CAD | 169788.696% |